S2970
Late-Breaking
ESTRO 2026
Harry G Bartelink 23 , Henk Struikmans 24 , Philip M Poortmans 25,26 1 Breast Radiation Unit, Sheba Medical Center, Ramat Gan, Israel. 2 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. 3 Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium. 4 Laboratory of Experimental Radiation Oncology, KU Leuven, Leuven, Belgium. 5 European Organisation for Research and Treatment of Cancer, Headquarters, Brussels, Belgium. 6 Department of Radiation Oncology, Institute Verbeeten, Tilburg, Netherlands. 7 Department of Radiation Oncology, University Hospital Saint Luc, Université Catholique de Louvain, Brussels, Belgium. 8 Department of Radiation Oncology, Comprehensive Cancer Center, Charité – University Medicine Berlin, Berlin, Germany. 9 Radiation Oncology, Vosspalais, Berlin, Germany. 10 Department of Radiation Oncology, Centre Georges François Leclerc, Dijon, France. 11 Department of Radiation Oncology, Sant Anna Hospital, Como, Italy. 12 Department of Radiation Oncology, Ospedale Valduce, Como, Italy. 13 Department of Radiation Oncology, Radiotherapiegroep, Deventer/Arnhem, Netherlands. 14 Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, Netherlands. 15 Department of Radiation Oncology, Gustave Roussy Cancer Centre, Villejuif, France. 16 Department of Radiation Oncology, University Hospital, Tübingen, Germany. 17 Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands. 18 Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland. 19 Department of Radiation Oncology, he Joseph Fishman Oncology Center, Rambam Health Care Campus, Haifa, Israel. 20 Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. 21 Department of Radiation Oncology, Medisch Spectrum Twente, Enschede, Netherlands. 22 Department of Radiation Oncology, Institut Curie, Paris, France. 23 Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. 24 Department of Radiation Oncology, HMC the Hague, Leidschendam, Netherlands. 25 Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium. 26 Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk- Antwerp, Belgium Purpose/Objective: The EORTC trial 22922/10925 investigates the impact of internal mammary and medial supraclavicular (IM- MS) radiation therapy (RT) in patients with stage I-III breast cancer (Clinicaltrials.gov NCT00002851). We present the subset analysis of patients without axillary nodal involvement (pN0), who were eligible for the trial (in case of centrally/medially located primary
respectively.
Conclusion: While the cumulative incidence of BCM at 20 years was statistically significantly lower after IM-MS-RT, the analysis of deaths not due to breast cancer or unknown cause showed a late separation of curves after about 15 years, resulting in no long-term benefit of IM-MS RT on overall survival. This may suggest that patients in the control arm tend to die earlier due to breast cancer while patients in the nodal-irradiation arm tend to die later due to other causes, including cause unknown. Keywords: Breast cancer, Nodal irradiation, Randomised trial
Proffered Paper 5582 Impact of Internal Mammary and Medial
Supraclavicular irradiation in pN0 breast cancer: 20 years results from the randomised EORTC trial 22922/10925. Orit Kaidar-Person 1,2 , Caroline G Weltens 3,4 , Catherine Fortpied 5 , Luc J Scheijmans 6 , Carine Y Kirkove 7 , Volker Budach 8,9 , Karine Peignaux-Casasnovas 10 , Mariacarla Valli 11,12 , Max Peters 13 , Femke van der Leij 14 , Sofia Rivera 15 , Nicola Weidner 16 , Desirée van den Bongard 17 , Claudia Linsenmeier 18 , Roxolyana Abdah-Bortnyak 19 , Shaymaa Hosni 20 , Eveline Koiter 21 , Antoine M Engelen 6 , Adinda Baten 3,4 , Lydia Champezou 5 , Alain Fourquet 22 ,
Made with FlippingBook - Share PDF online